Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Metastatic Pheochromocytoma/Paraganglioma
NCT01967576Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in pheochromocytoma and Paraganglioma (PGL), sponsored by National Cancer Institute. Primary endpoint: Number of Participants With Clinical Response (Partial Response + Complete Response) up to 40.6 months. Started Oct 2013; status: completed.
02
Drugs
axitinib
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT01967576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01967576.